1,121 reports of this reaction
1.3% of all FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE reports
#20 most reported adverse reaction
PRODUCTIVE COUGH is the #20 most commonly reported adverse reaction for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 1,121 FDA adverse event reports linking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE to PRODUCTIVE COUGH. This represents approximately 1.3% of all 88,399 adverse event reports for this drug.
Patients taking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE who experience productive cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCTIVE COUGH is a less commonly reported adverse event for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, but still significant enough to appear in the safety profile.
In addition to productive cough, the following adverse reactions have been reported for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE:
The following drugs have also been linked to productive cough in FDA adverse event reports:
PRODUCTIVE COUGH has been reported as an adverse event in 1,121 FDA reports for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCTIVE COUGH accounts for approximately 1.3% of all adverse event reports for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, making it a notable side effect.
If you experience productive cough while taking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.